TransMedics Group Inc. (TMDX)
1 Compelling Reason to Buy and Hold TransMedics Group Stock Forever
Donor organs make the difference between life and death for thousands of people every year. But there are two big problems.
TransMedics: A Very Bullish Last Few Months Could Change Sentiment
TransMedics Group, Inc. shows strong Q4 results with revenue at $121.6m and EPS at $0.2, beating estimates and reassuring investors. TMDX's long-term growth potential is supported by its innovative organ transplant technology and ambitious goals for increasing transplant volumes. Risks include margin expansion challenges, competition from cost-effective alternatives like NRP, and complexities in transitioning to an aviation logistics company.
1 Turnaround Growth Stock Down 60% That Could Double, According to Wall Street
With the recent market sell-off, now is potentially the time for investors to find their next big winner. After all, if one had invested in stocks during the bear markets of late 2018, the Covid drawdown of 2020, or the interest rate driven drawdown of 2022, you likely would have made out quite well.
Down 62%. Should You Buy TransMedics Stock on the Dip?
It's been a rough several months for TransMedics Group (TMDX -2.12%) shareholders. The stock has been beaten down by about 62% from the peak it set last August.
TransMedics: Aggressive Guidance Largely Ignored By The Market
TransMedics' stock has rebounded modestly in recent months on the back of a strong fourth quarter performance. Continued market growth and TransMedics return to gaining market share should help to boost investor confidence going forward. While TransMedics's share price remains well below all-time highs, its valuation still implies solid growth going forward.
TransMedics Stock Rises as Q4 Earnings & Revenues Beat Estimates
TMDX's fourth-quarter earnings depict strength in the company's net product revenues and services revenues. A rise in operating income bodes well for the stock.
TransMedics Group, Inc. (TMDX) Q4 2024 Earnings Call Transcript
TransMedics Group, Inc. (NASDAQ:TMDX ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President and Chief Executive Officer Gerardo Hernandez - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Josh Jennings - TD Cowen Bill Plovanic - Canaccord Suraj Kalia - Oppenheimer Chris Pasquale - Nephron Research Matthew O'Brien - Piper Sandler David Rescott - Baird Mike Matson - Needham & Company Operator Good afternoon, and welcome to the TransMedics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
TransMedics (TMDX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
TransMedics (TMDX) Q4 Earnings and Revenues Beat Estimates
TransMedics (TMDX) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.12 per share a year ago.
TransMedics' Revenue Surged 49.8% in Q4
TransMedics Group (TMDX -2.22%), a leader in organ transplant technology, released its fourth-quarter results on Feb. 27. The company reported diluted earnings per share (EPS) of $0.19, outpacing the $0.16 forecast by analysts, and revenue of $121.6 million exceeded the $109 million estimate.
TransMedics: Data Points To A Miss On Low Expectations, Followed By Big Improvement
TransMedics is expected to report disappointing Q4 results, with industry data suggesting it will likely miss and come in at the low end of guidance. The company's Q3 performance was poor, underperforming in Heart, Lung, and Liver transplants, leading to a significant loss of investor confidence. Despite a challenging Q4, early signs indicate a stronger start to 2025, potentially allowing management to provide more optimistic guidance for the year. Yet, I think they'll take the conservative route.
Curious about TransMedics (TMDX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for TransMedics (TMDX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
